Record Nr.	UNINA9910810075403321
Titolo	BACE : lead target for orchestrated therapy of Alzheimer's disease / / edited by Varghese John
Pubbl/distr/stampa	Hoboken, NJ, : John Wiley & Sons, c2010
ISBN	1-282-49175-X 9786612491757 0-470-59408-X 0-470-59407-1
Edizione	[1st ed.]
Descrizione fisica	1 online resource (284 p.)
Altri autori (Persone)	JohnVarghese <1958->
Disciplina	618.976831
Soggetti	Alzheimer's disease - Chemotherapy Aspartic proteinases - Inhibitors - Therapeutic use Amyloid beta-protein precursor
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	 BACE; CONTENTS; PREFACE; ACKNOWLEDGMENTS; CONTRIBUTORS; CHAPTER 1 BACE, APP PROCESSING, AND SIGNAL TRANSDUCTION IN ALZHEIMER'S DISEASE; 1.1 Introduction; 1.2 BACE Cleavage of APP as a Molecular Switching Mechanism; 1.3 AD: An Imbalance in Cellular Dependence?; 1.4 BACE Cleavage, Caspase Cleavage, and Neuronal Trophic Dependence; 1.5 BACE Cleavage of APP, Dependence Receptors, and Alzheimer Pathology; 1.6 Key Mutations Proximal of APP Processing to A; 1.7 Final Remarks; CHAPTER 2 IDENTIFICATION OF BACE AS A TARGET IN ALZHEIMER'S DISEASE; 2.1 Introduction; 2.2 The Search for -Secretase 2.3 Validation of the BACE Target 2.4 Final Remarks; CHAPTER 3 BACE BIOLOGICAL ASSAYS; 3.1 Introduction; 3.2 Clinical and Physiological Hallmarks of Alzheimer's Disease (AD); 3.3 APP Processing; 3.4 Aspartyl Protease Classification; 3.5 BACE Structure; 3.6 Mechanism, Kinetics, Inhibition, and Specificity; 3.7 Assay Strategies for Inhibitor Finding and Development; 3.8 Common Assays Used to Identify and Study Inhibitors; 3.9 BACE Assays; 3.10 Final Remarks; CHAPTER 4 PEPTIDIC, PEPTIDOMIMETIC, AND HTS-DERIVED BACE INHIBITORS; 4.1

1.

	Introduction; 4.2 Elan/Pharmacia (Pfizer)
	4.3 Oklahoma Medical Research Foundation (OMRF)/Multiple
	Collaborators 4.4 Eli Lilly; 4.5 Merck; 4.6 GlaxoSmithKline; 4.7 Schering
	Plough; 4.8 Bristol-Myers Squibb; 4.9 Novartis; 4.10 Amgen; 4.11
	Wyeth; 4.12 Final Remarks; CHAPTER 5 FRAGMENT-BASED APPROACHES
	FOR IDENTIFICATION OF BACE INHIBITORS; 5.1 Introduction; 5.2
	Biophysical Methods Applied to BACE Fragment Screens; 5.3 BACE
	Inhibitors Identified by Fragment Screening; 5.4 Final Remarks;
	CHAPTER 6 STRUCTURE-BASED DESIGN OF BACE INHIBITORS:
	TECHNICAL AND PRACTICAL ASPECTS OF PREPARATION, 3-
	DIMENSIONAL STRUCTURE, AND COMPUTATIONAL ANALYSIS
	6.1 Introduction 6.2 Preparation of BACE for Structural Studies; 6.3
	Crystallographic Studies of BACE; 6.4 Structural Studies with BACE
	Inhibitors: Peptidomimetics and Nonpeptidomimetics; 6.5
	Computational Approaches; 6.6 Final Remarks; CHAPTER 7
	PHARMACOLOGICAL MODELS FOR PRECLINICAL TESTING: FROM MOUSE
	TO DOG TO NONHUMAN PRIMATES; 7.1 Introduction; 7.2 BACE 1 and
	Mouse Models of AD; 7.3 Testing BACE Inhibitors in the Canine Model
	of Human Aging and AD; 7.4 BACE Inhibitors and Nonhuman Primates;
	7.5 Final Remarks
	(ADME) FEELCACY, AND TOYICOLOCY FOR BACE INHUBITODS 2.4
	(ADME), EFFICACY, AND TOXICOLOGY FOR BACE INHIBITORS 8.1
	Introduction, 6.2 Development of BACE Inhibitors with Optimized ADME
	Properties, 6.5 III VIVO Efficacy of DACE Infinibitors, 6.4 Toxicology of BACE Inhibitors: 8.5 Einst Romarks: CHARTER 6.CLINICAL TRIALS EOR
	DISEASE-MODIEVING DRUGS SUCH AS BACE INHIBITORS: 0.1
	Introduction: 9.2 Undate on Beta-Amyloid Therapies in Clinical
	Development: 9.3 Clinical Development of BACE Inhibitors and Other
	Disease-Modifying Drugs: 9.4 Final Remarks
	CHAPTER 10 FUTURE STRATEGIES FOR DEVELOPMENT OF NOVEL BACE
	INHIBITORS' ANTI-APP -SITE ANTIBODY AND APP BINDING SMALL
	MOLECULE APPROACHES FOR ALZHEIMER'S DISEASE
Sommario/riassunto	BACE inhibitors and their use in the treatment of Alzheimer's Disease
Sommano/nassunto	BACE (R-site of APP cleaving enzyme) is a critical component in
	Alzheimer's Disease (AD), and the development of BACE inhibitors
	shows great potential as a therapy for the disease. BACE: Lead Target
	for Orchestrated Therapy of Alzheimer's Disease covers virtually all
	aspects of BACE from initial identification, discovery of inhibitors, and
	challenges in clinical development, while providing a global
	understanding essential for productive and successful drug discovery.
	This book details the story of the disc